Literature DB >> 31345339

Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.

Takamasa Nakasuka1, Eiki Ichihara2, Go Makimoto3, Yoshinobu Maeda3, Katsuyuki Kiura1.   

Abstract

Entities:  

Year:  2019        PMID： 31345339     DOI： 10.1016/j.jtho.2019.03.009

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.

Authors:  Noura J Choudhury; Robert J Young; Matthew Sellitti; Alexandra Miller; Alexander Drilon
Journal:  JCO Precis Oncol       Date:  2020-11-02

2.  Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study.

Authors:  Ziwei Huang; Qi Xiong; Zhi Cui; Haitao Tao; Sujie Zhang; Lijie Wang; Pengfei Cui; Shixue Chen; Di Huang; Bo Yang; Yi Hu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 3.  Anaplastic lymphoma kinase-special immunity and immunotherapy.

Authors:  Ye Guo; Hanfei Guo; Yongfei Zhang; Jiuwei Cui
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

4.  Systematic Analysis and Identification of Molecular Subtypes of TRP-Related Genes and Prognosis Prediction in Lung Adenocarcinoma.

Authors:  Yang Guo; Ning Liu
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501

Review 5.  Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC).

Authors:  Aaron C Tan; Nick Pavlakis
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

6.  Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments.

Authors:  Bo Ling; Xianjiu Liao; Yuanhe Huang; Lingling Liang; Yan Jiang; Yaqin Pang; Guangzi Qi
Journal:  Int J Oncol       Date:  2019-11-28       Impact factor: 5.650
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.